- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Case Study Spotlights FCS as a Top-Ranking Performer in the Oncology Care Model
A recently published case study by Florida Cancer Specialists & Research Institute showcased the practice’s multi-year track record of delivering savings as a participant in the Oncology Care Model (OCM) when compared with OCM and non-OCM practices nationally.
Fort Myers, Florida — A recently published case study by Florida Cancer Specialists & Research Institute (FCS) showcased the practice’s multi-year track record of delivering savings as a participant in the Oncology Care Model (OCM) when compared with OCM and non-OCM practices nationally.
Amongst more than 125 participating practices nationwide, FCS emerged as a leader in value-based care oncology in having successfully reduced Medicare expenditures by nearly $170 million in aggregate.
“Our success in this program is indicative of the resources, dedication, investment and overall integrity of FCS’ commitment to healthcare reform,” said Michael Diaz, MD, president and managing physician, FCS. “Patients can find reassurance knowing that we have put elaborate measures in place to not only utilize state of the art technologies and therapeutics to maximize treatment outcomes but optimize care delivery to positively influence their overall cancer journey.”
Employers Shift to Equity-Focused Strategies as Health Costs Outpace Wages
October 31st 2024As health care costs escalate, a new survey reveals that 74% of employers are grappling with the impact on employee wages and benefits, with many anticipating further cost-shifting to their workforce.
Read More
Sustaining Compassionate Trauma Care Across Communities
September 30th 2024September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In our final episode, we speak with Lyndra Bills, MD, and Shari Hutchison, MS.
Listen
Targeting Progression: Amivantamab’s Role in NSCLC After Osimertinib
October 24th 2024Amivantamab's role in non–small cell lung cancer (NSCLC) has been a highlight of the lung cancer space this year, with the 2 most recent approvals based on data from the MARIPOSA and MARIPOSA-2 trials.
Read More
